

## **Curriculum Vitae**

### **Personal Information**

**Full Name:** Marco Marchisio

**Date of Birth:** 30 March 1965

**Place of Birth:** Ferrara, Italy

**Nationality:** Italian

**Fiscal Code:** MRCMRC65C30D548A

### **Current Position**

Full Professor of Human Anatomy

“G. d’Annunzio” University of Chieti-Pescara – Medical School

### **Work Experience**

#### **2019 – Present**

Full Professor of Human Anatomy

“G. d’Annunzio” University of Chieti-Pescara

#### **2006 – 2019**

Associate Professor of Human Anatomy

“G. d’Annunzio” University of Chieti-Pescara

#### **2004 – 2006**

Assistant Professor of Human Anatomy

“G. d’Annunzio” University of Chieti-Pescara

#### **2002 – 2004**

Contract Researcher

Center of Excellence on Aging, Foundation “G. d’Annunzio” University, Chieti

#### **2001**

Visiting Fellow

Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

#### **2001**

FIRC Fellowship – Italian Foundation for Cancer Research

#### **2000 – 2001**

AIDS Fellowship – Italian Ministry of Health

#### **1997**

Visiting Fellow

Babraham Institute, Cambridge, UK

### **Education and Training**

#### **1997 – 1999**

Ph.D. in Cellular and Molecular Biology

Institute of Human Anatomy, University of Ferrara, Italy

## **1996 – 1997**

Research Training

Institute of Human Anatomy, University of Ferrara, Italy

## **1995**

Doctor of Sciences in Biological Sciences

University of Ferrara, Italy

## **2000 – 2001**

Postdoctoral Research

Department of Experimental Clinical Medicine, Institute of Microbiology, University of Bologna, Italy

## **Research Interests**

Research activity focused on lipid-dependent signal transduction pathways during cell growth and differentiation.

Key contributions include:

- Identification and functional role of PKC, PI-PLC and PI3K isoforms in both whole cell and nuclear compartments
- Study of inositide-related enzymes in overcoming differentiation block in APL-derived promyelocytes (HL-60, NB4) induced by agonists (trans-retinoic acid, As<sub>2</sub>O<sub>3</sub>)
- Investigation of PLC isoforms in breast cancer development and progression
- Identification of molecular targets for anticancer (antineoplastic) strategies

## **Scientific Skills**

- Functional proteomics
- Immunochemical, immunocytochemical and immunohistochemical analyses
- Modulation of protein expression (positive and negative)
- Enzymatic activity assays
- Flow cytometry, including:
  - Cell phenotyping
  - High-speed cell sorting
  - Quantitative imaging flow cytometry

## **Scientific Output**

- Peer-reviewed publications: **161**
- Citations: **4266**

- H-index: **45**
- Total Impact Factor: **649.583**

### **Professional Memberships**

- Italian Society of Anatomy and Histology (SIAI)
- Italian Society of Histochemistry (SII)
- Italian Society of Cytometry (GIC)
- Founding Member, Stem Te.Ch. Group
- Stem Cell Research Italy (SCRI)
- European Society for Clinical Cell Analysis (ESCCA)

### **Honours and Awards**

#### **2001**

FIRC Fellowship for Cancer Research (USUHS, Bethesda, USA)

#### **1999**

“Young Researchers Project” Award

University of Ferrara, Italy

#### **1997**

Short-term Fellowship

National Research Council (CNR), Italy – Babraham Institute, Cambridge, UK

### **Funded Research Projects**

#### **2013**

Unit Leader – Cystic Fibrosis Research Foundation (ONLUS)

“The role of vascular endothelium in cystic fibrosis inflammation”

(12 months, cod. FFC#19/2013)

#### **2012**

Unit Leader – Cystic Fibrosis Research Foundation (ONLUS)

“The role of vascular endothelium in cystic fibrosis inflammation”

(12 months, cod. FFC #17/2012)

#### **1999**

Principal Investigator – University of Ferrara

“Evaluation of cytokine involvement in granulocyte differentiation induced by ATRA in APL cells”

(12 months)

### **Participation in Research Projects**

## 2023

PRIN Project

DART-CRAFT – A dopable bioink augmented tissue engineering incraniofacial reconstruction: Innovative pipeline for drug desig and selective delivery through funzionalized polimer nanoparticler -D73C23002070001 – PNRR-POC-2023-12378222

## 2022

PRIN Project

2022YXHEET – Hybrid E/M AEC States:Insights into therelationship between stemness and regenerative role -D53D23012080006 - 2022YXHEET

## 2013

Carichieti Foundation

“Amniotic Cells in Regenerative Medicine: Osteogenic Differentiation, Scaffold Development, and Therapeutic Efficacy” (36 months)

## 2010

FIRB Program

“Tumor stem cells: signal transduction pathways as therapeutic targets” (24 months)

## 2009

Carichieti Foundation

“Amniotic fluid cells in regenerative medicine” (36 months)

## 2005

PRIN Project

“Nuclear events regulating cell cycle progression: role of PKC alpha and delta” (24 months)

---

## Selected Peer-Reviewed Publications

- Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. Secchiero P, Gibellini D, Flamand L, Robuffo I, **Marchisio M**, Capitani S, Gallo RC, Zauli G. *J Immunol.* 1997 Oct 1;159(7):3412-23. PMID: 9317140 IF: 6,937
- The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells. Zauli G, Gibellini D, Vitale M, Secchiero P, Celeghini C, Bassini A, Pierpaoli S, **Marchisio M**, Guidotti L, Capitani S. *Blood.* 1998 Jul 15;92(2):472-80. PMID: 9657746 IF: 8,372
- Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC-zeta translocation to the nucleus of NGF-treated PC12 cells. Neri LM, Martelli AM, Borgatti P, Colamussi ML, **Marchisio M**, Capitani S. *FASEB J.* 1999 Dec;13(15):2299-310. PMID: 10593877 IF: 11,880
- Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Bertagnolo V, Neri LM, **Marchisio M**, Mischiati C, Capitani S. *Cancer Res.* 1999 Feb 1;59(3):542-6. IF: 8,614
- Phospholipase C delta2 expression characterizes the neoplastic transformation of the human gastric mucosa. **Marchisio M**, Di Baldassarre A, Angelucci D, Caramelli E, Cataldi A, Castorina S, Antonucci A, Di Giovannantonio L, Schiavone C, Di Biagio R, Falconi M, Zauli G, Miscia S. *Am J Pathol.* 2001 Sep;159(3):803-8. doi: 10.1016/s0002-9440(10)61754-3. PMID: 11549571 IF: 7,103
- Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Lanuti P, Bertagnolo V,

Pierdomenico L, Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S, **Marchisio M**. *Cell Res*. 2009 Sep;19(9):1079-89. doi: 10.1038/cr.2009.80. Epub 2009 Jun 30. PMID: 19564891 IF: 8,151

- High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process. Grassilli S, Brugnoli F, Lattanzio R, Rossi C, Perracchio L, Mottolese M, **Marchisio M**, Palomba M, Nika E, Natali PG, Piantelli M, Capitani S, Bertagnolo V. *Oncotarget*. 2014 Jun 30;5(12):4320-36. doi: 10.18632/oncotarget.2011. PMID: 24962430 IF: 6,359

- Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. Verginelli F, Perconti S, Vespa S, Schiavi F, Prasad SC, Lanuti P, Cama A, Tramontana L, Esposito DL, Guarnieri S, Sheu A, Pantalone MR, Florio R, Morgano A, Rossi C, Bologna G, **Marchisio M**, D'Argenio A, Taschin E, Visone R, Opocher G, Veronese A, Paties CT, Rajasekhar VK, Söderberg-Nauclér C, Sanna M, Lotti LV, Mariani-Costantini R. *Acta Neuropathol*. 2018 May;135(5):779-798. doi: 10.1007/s00401-017-1799-2. Epub 2018 Jan 5. PMID: 29305721 IF: 18,174

- Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival. Sorrentino C, Yin Z, Ciummo S, Lanuti P, Lu LF, **Marchisio M**, Bellone M, Di Carlo E. *J Immunother Cancer*. 2019 Jul 31;7(1):201. doi: 10.1186/s40425-019-0668-z. PMID: 31366386 IF: 9,913

- Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. Ciardiello C, Leone A, Lanuti P, Roca MS, Moccia T, Minciacchi VR, Minopoli M, Gigantino V, De Cecio R, Ripa M, Petti L, Capone F, Vitagliano C, Milone MR, Pucci B, Lombardi R, Iannelli F, Di Gennaro E, Bruzzese F, **Marchisio M**, Carriero MV, Di Vizio D, Budillon A. *J Exp Clin Cancer Res*. 2019 Jul 18;38(1):317. doi: 10.1186/s13046-019-1317-6. PMID: 31319863 IF: 7,068

Chieti, 21 marzo 2026

Prof. Marco Marchisio